Form Change Summary

Contents

Disease Classification (F2402 R8)

General Update

To prevent duplicate reporting and ease reporting burden, for subsequent infusions for the same recipient with the same disease and diagnosis date, assessments at diagnosis no longer need to be reported for the following diseases: AML, ALL, MDS, and MPN. The validations and floating text have been updated throughout the form to align with these changes.

Acute Myeloid Leukemia (AML)

- **Q3 ("Specify the AML classification")**
  - Update: Disease classifications have been updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community. (See (Arber, 2022) (Hartmut Dohner, 2022))
    ~See table below for detailed list of changes
  - Rationale: Capture current published and relevant disease classifications.

2402 R7	Data Change Description	2402 R8
AML with recurrent genetic abnormalities	Replacement	**AML with defining genetic abnormalities**
AML with t(9;11)(p22.3;q23.3); MLLT3-KMT2A	Replacement	Acute myeloid leukemia with *MLLT3::KMT2A* fusion
AML with 11q23 (MLL) abnormalities (i.e., t(4;11), t(6;11), t(9;11))	Replacement	Acute myeloid leukemia with other *KMT2A* rearrangements
AML with t(6;9)(p23;q34.1); DEK-NUP214	Replacement	Acute myeloid leukemia with *DEK::NUP214* fusion
AML with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2)	Replacement	Acute myeloid leukemia with *MECOM(EVI1), GATA2* rearrangement
	Addition	Acute myeloid leukemia with Other *MECOM* rearrangements
AML (megakaryoblastic) with t(1;22)(p13.3;13.3); RBM15-MKL1	Replacement	Acute myeloid leukemia with *RBM15::MRTFA* fusion

AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1	Replacement	Acute myeloid leukemia with *RUNX1::RUNX1T1* fusion
AML with inv(16)(p13.1;1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Replacement	Acute myeloid leukemia with *CBFB::MYH11* fusion
APL with PML-RARA	Replacement	Acute promyelocytic leukemia with *PML::RARA* fusion
	Addition	Acute promyelocytic leukemia with *other RARA* fusions
AML with BCR-ABL1 (provisional entity)	Replacement	Acute myeloid leukemia with *BCR::ABL1* fusion
AML with mutated NPM1	Replacement	Acute myeloid leukemia with *NPM1* mutation
AML with biallelic mutations of CEBPA	Replacement	Acute myeloid leukemia with *CEBPA* mutation
AML with mutated RUNX1 (provisional entry)	Removal	
AML with myelodysplasia – related changes	No change	Acute myeloid leukemia, myelodysplasia-related
Therapy related AML (t-AML)	Removal	
	Addition	Acute myeloid leukemia with *NUP98* rearrangement
	Addition	Acute myeloid leukemia with mutated TP53
	Addition	Acute myeloid leukemia with other defined genetic alterations
AML, not otherwise specified	Replacement	**Acute myeloid leukemia, defined by differentiation**
AML, not otherwise specified	Removal	
AML, minimally differentiated	Replacement	Acute myeloid leukemia with minimal differentiation
AML without maturation	Replacement	Acute myeloid leukemia without maturation
AML with maturation	Replacement	Acute myeloid leukemia with maturation
Acute myelomonocytic leukemia	Replacement	Acute myelomonocytic leukemia
Acute monoblastic/acute monocytic leukemia	Replacement	Acute monocytic leukemia

Acute erythroid leukemia (erythroid/myeloid and pure erythroleukemia)	Replacement	Acute erythroid leukemia
Acute megakaryoblastic leukemia	No change	Acute megakaryoblastic leukemia
Acute basophilic leukemia	No change	Acute basophilic leukemia
Acute panmyelosis with myelofibrosis	Removal	
Myeloid sarcoma	No change	Myeloid sarcoma
Myeloid leukemia associated with Down syndrome	Removal	

Acute Lymphoblastic Leukemia (ALL)

- **Q104 ("Specify ALL classification")**
  - Update: Disease classifications have been updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community.
    ~See table below for detailed list of changes
  - Rationale: Capture current published and relevant disease classifications.

2402 R7	**Data Change Description**	**2402 R8**
B-lymphoblastic leukemia/lymphoma	No change	**B-lymphoblastic leukemia/lymphoma**
B-lymphoblastic leukemia/lymphoma, NOS (B-cell ALL, NOS)	Replacement	B-lymphoblastic leukemia/lymphoma, NOS
B-lymphoblastic leukemia/lymphoma with Hyperdiploidy (51-65 chromosomes)	Replacement	B-lymphoblastic leukemia/lymphoma with high hyperdiploidy
B-lymphoblastic leukemia/lymphoma with Hypodiploidy (<46 chromosomes)	Replacement	B-lymphoblastic leukemia/lymphoma with hypodiploidy
B-lymphoblastic leukemia/lymphoma, with iAMP21	No change	B-lymphoblastic leukemia/lymphoma, with iAMP21
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1	Replacement	B-lymphoblastic leukemia/lymphoma with BCR::ABL1 fusion
B-lymphoblastic leukemia/lymphoma with BCR-ABL1-like (provisional entity)	Replacement	B-lymphoblastic leukemia/lymphoma with BCR::ABL1-like features
B-lymphoblastic leukemia/lymphoma with t(v;11q23.3); KMT2A rearranged	Replacement	B-lymphoblastic leukemia/lymphoma with KMT2A rearrangement

B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1	Replacement	B-lymphoblastic leukemia/lymphoma with ETV6::RUNX1 fusion
	Addition	B-lymphoblastic leukemia/lymphoma with ETV6::RUNX1-like features
B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1	Replacement	B-lymphoblastic leukemia/lymphoma with TCF3::PBX1 fusion
B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH	Replacement	B-lymphoblastic leukemia/lymphoma with IGH::IL3 fusion
	Addition	B-lymphoblastic leukemia/lymphoma with TCF3::HLF fusion
	Addition	**B-lymphoblastic leukemia/lymphoma with other defined genetic abnormalities**
	Addition	B-lymphoblastic leukemia/lymphoma with DUX4 rearrangement
	Addition	B-lymphoblastic leukemia/lymphoma with IG::MYC fusion
	Addition	B-lymphoblastic leukemia/lymphoma with MEF2D rearrangement
	Addition	B-lymphoblastic leukemia/lymphoma with ZNF384 rearrangement
	Addition	B-lymphoblastic leukemia/lymphoma with NUTM1 rearrangement
	Addition	B-lymphoblastic leukemia/lymphoma with PAX5alt abnormalities
	Addition	B-lymphoblastic leukemia/lymphoma with PAX5 p.P80R abnormalities
T-cell lymphoblastic leukemia / lymphoma	No change	**T-cell lymphoblastic leukemia / lymphoma**
T-cell lymphoblastic leukemia / lymphoma (Precursor T-cell ALL)	Replacement	T-lymphoblastic leukemia / lymphoma
Early T-cell precursor lymphoblastic leukemia	Replacement	Early T-precursor lymphoblastic leukemia / lymphoma
	Addition	Early T-precursor lymphoblastic leukemia / lymphoma with BCL11B rearrangement

NK-cell lymphoblastic leukemia/lymphoma	No change	**NK-cell lymphoblastic leukemia/lymphoma**
Natural killer (NK)- cell lymphoblastic leukemia / lymphoma	No change	Natural killer (NK)- cell lymphoblastic leukemia / lymphoma

Acute Leukemias of Mixed or Ambiguous Lineage

- **Subheading title ("Acute Leukemias of Mixed or Ambiguous Lineage")**
  - Update: The title of this subsection is being updated from "Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms" to "Acute Leukemias of Mixed or Ambiguous Lineage."
  - Rationale: Capture current published and relevant disease classifications.

- **Q180 ("Specify acute leukemias of mixed or ambiguous lineage")**
  - Update: Disease classifications have been updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community.
    ~See table below for detailed list of changes
  - Rationale: Capture current published and relevant disease classifications.

2402 R7	Data Change Description	2402 R8
Acute Leukemias of Ambiguous Lineage or Other Myeloid Neoplasms	Replacement	**Acute Leukemias of Mixed or Ambiguous Lineage**
Blastic plasmacytoid dendritic cell neoplasm	No change	Blastic plasmacytoid dendritic cell neoplasm
Acute undifferentiated leukemia	No change	Acute undifferentiated leukemia
Mixed-phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 fusion	Replacement	Mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion
Mixed-phenotype acute leukemia with t(v;11q23.3); KMT2A rearranged	Replacement	Mixed-phenotype acute leukemia with KMT2A rearrangement
	Addition	Mixed-phenotype acute leukemia with ZNF384 rearrangement
	Addition	Acute leukemia of ambiguous lineage with BCL11B rearrangement
Mixed-phenotype acute leukemia, B/myeloid, NOS	Replacement	Mixed-phenotype acute leukemia, B/myeloid

Mixed-phenotype acute leukemia, T/myeloid, NOS	Replacement	Mixed-phenotype acute leukemia, T/myeloid
	Addition	Mixed-phenotype acute leukemia, rare types
Other acute leukemia of ambiguous lineage or myeloid neoplasm	Replacement	Acute leukemia of ambiguous lineage, NOS

Myelodysplastic Syndrome (MDS)

- **Q195 ("What was the MDS subtype at diagnosis?")**
  - Update: Disease classifications have been updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community. (See (Khoury, 2022)
    ~See table below for detailed list of changes
  - Rationale: Capture current published and relevant disease classifications.

2402 R7	Data Change Description	2402 R8
	Addition	**MDS with defining genetic abnormalities**
Myelodysplastic syndrome with isolated del(5q)	Replacement	MDS with low blasts and isolated 5q deletion (MDS-5q)
	Addition	MDS with low blasts and *SF3B1* mutation (MDS-SF3B1)
	Addition	MDS with low blasts and ring sideroblasts (>=15% ring sideroblasts and wild type SF3B1)
	Addition	MDS with biallelic TP53 inactivation (MDS-biTP53)
	Addition	**MDS, morphically defined**
	Addition	MDS, with low blasts (MDS-LB; <5% BM, <2%PB)
	Addition	MDS, hypoplastic (MDS-h) <=25% cellularity by age
Myelodysplastic syndrome with multilineage dysplasia (MDS-MLD)	Removal	
Myelodysplastic syndrome with single lineage dysplasia (MDS-SLD)	Removal	

Myelodysplastic syndrome with ring sideroblasts	Removal	
MDS with excess blasts-1 (MDS-EB-1)	Replacement	MDS with increased blasts (MDS-IB1)
MDS with excess blasts-2 (MDS-EB-2)	Replacement	MDS with increased blasts (MDS-IB2)
	Addition	MDS with fibrosis (MDS-f)
MDS, unclassifiable	Removal	
	Addition	**Childhood myelodysplastic neoplasms (MDS).**
Refractory cytopenia of childhood	Replacement	Childhood MDS with low blasts, hypocellular
	Addition	Childhood MDS with low blasts, not otherwise specified
	Addition	Childhood MDS with increased blasts
	Addition	**Myelodysplastic/myeloproliferative neoplasms.**
Chronic myelomonocytic leukemia	Replacement	Chronic myelomonocytic leukemia (CMML), Myelodysplastic
	Addition	Chronic myelomonocytic leukemia (CMML), Myeloproliferative
MDS/MPN with ring sidero bloasts and thrombocytosis	Replacement	Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis
	Addition	MDS/MPN with ring sidero bloasts (>=15% ring sideroblasts and wild type SF3B1) and thrombocytosis
Juvenile myelomonocytic leukemia (JMML)	No change	Juvenile myelomonocytic leukemia (JMML)
Atypical chronic myeloid leukemia (aCML), BCR-ABL1-	Replacement	Myelodysplastic/myeloproliferative neoplasm with neutrophilia
Myelodysplastic syndrome / myeloproliferative neoplasm, unclassifiable	Replacement	Myelodysplastic/myeloproliferative neoplasm, NOS

- **Q196 ("Specify Myelodysplastic syndrome, unclassifiable (MDS-U)")**
  - Update: This question will be disabled on R8.
  - Rationale: It is no longer necessary to capture this data.

- **Q235 ("Specify the MDS subtype or AML after transformation")**
  - Update: Disease classifications have been updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community. (See (Khoury, 2022)
    ~See table below for detailed list of changes
  - Rationale: Capture current published and relevant disease classifications.

2402 R7	Data Change Description	2402 R8
	Addition	**MDS with defining genetic abnormalities**
Myelodysplastic syndrome with isolated del(5q)	Replacement	MDS with low blasts and isolated 5q deletion (MDS-5q)
	Addition	MDS with low blasts and *SF3B1* mutation (MDS-SF3B1)
	Addition	MDS with low blasts and ring sideroblasts (>=15% ring sideroblasts and wild type SF3B1)
	Addition	MDS with biallelic TP53 inactivation (MDS-biTP53)
	Addition	**MDS, morphically defined**
	Addition	MDS, with low blasts (MDS-LB; <5% BM, <2%PB)
	Addition	MDS, hypoplastic (MDS-h) <=25% cellularity by age
Myelodysplastic syndrome with ring sideroblasts	Removal	
MDS-RS with single lineage dysplasia (MDS-RS-SLD)	Removal	
MDS-RS with multilineage dysplasia (MDS-RS-MLD)	Removal	
Myelodysplastic syndrome with excess blasts (MDS-EB)	Removal	
MDS with excess blasts-1 (MDS-EB-1)	Replacement	MDS with increased blasts (MDS-IB1)
MDS with excess blasts-2 (MDS-EB-2)	Replacement	MDS with increased blasts (MDS-IB2)

	Addition	MDS with fibrosis (MDS-f)
Myelodysplastic syndrome (MDS), unclassifiable	Removal	
	Addition	**Childhood myelodysplastic neoplasms (MDS)**
Refractory cytopenia of childhood	Replacement	Childhood MDS with low blasts, hypocellular
	Addition	Childhood MDS with low blasts, not otherwise specified
	Addition	Childhood MDS with increased blasts
	Addition	**Myelodysplastic/myeloproliferative neoplasms**
Chronic myelomonocytic leukemia (CMMoL)	Replacement	Chronic myelomonocytic leukemia (CMML), Myelodysplastic
	Addition	Chronic myelomonocytic leukemia (CMML), Myeloproliferative
Atypical chronic myeloid leukemia	Replacement	Myelodysplastic/myeloproliferative neoplasm with neutrophilia
MDS/MPN with ring sideroblasts and thrombocytosis (MDS / MPN-RS-T)	Replacement	Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis
	Addition	MDS/MPN with ring sidero bloasts (>=15% ring sideroblasts and wild type SF3B1) and thrombocytosis
Myelodysplastic syndrome / myeloproliferative neoplasm, unclassifiable	Replacement	Myelodysplastic/myeloproliferative neoplasm, NOS
	Addition	**Transformed to AML**
Transformed to AML	No Change	Transformed to AML

- **Q236 ("Specify Myelodysplastic syndrome, unclassifiable (MDS-U)")**
  - Update: This question will be disabled on R8.
  - Rationale: It is no longer necessary to capture this data.

Myeloproliferative Neoplasms (MPN)

- **Q275 ("What was the MPN subtype at diagnosis?")**

- Update: Disease classifications have been updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community. (See (Khoury, 2022)
  ~See table below for detailed list of changes
- Rationale: Capture current published and relevant disease classifications.

2402 R7	Data Change Description	2402 R8
	Addition	**Myeloproliferative neoplasms**
Chronic neutrophilic leukemia	No change	Chronic neutrophilic leukemia
Chronic eosinophilic leukemia, not otherwise specified (NOS)	Replacement	Chronic eosinophilic leukemia
Essential thrombocythemia	No change	Essential thrombocythemia
Myeloproliferative neoplasm (MPN), unclassifiable	Replacement	Myeloproliferative neoplasm, not otherwise specified
Myeloid/lymphoid neoplasms with PDGFRA rearrangement	Removal	
Myeloid/lymphoid neoplasms with PDGFRB rearrangement	Removal	
Myeloid/lymphoid neoplasms with FGFR1 rearrangement	Removal	
Myeloid/lymphoid neoplasms with PCM1-JAK2	Removal	
Polycythemia vera (PCV)	No change	Polycythemia vera (PCV)
Primary myelofibrosis (PMF)	No change	Primary myelofibrosis (PMF)
Mastocytosis	No change	**Mastocytosis**
Cutaneous mastocytosis (CM)	No change	Cutaneous mastocytosis (CM)
Systemic mastocytosis	No change	Systemic mastocytosis
Mast cell sarcoma (MCS)	No change	Mast cell sarcoma (MCS)

- **Q276 ("Specify systemic mastocytosis")**
  - Update: The option "Bone marrow mastocytosis" has been added to the option list. This was added to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community.
  - Rationale: Capture current published and relevant disease classifications.

Other Leukemia (OL)

- **Q388 ("Specify the other leukemia classification")**
  - Update: Disease classifications have been updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community.
    ~See table below for detailed list of changes
  - Rationale: Capture current published and relevant disease classifications.

2402 R7	Data Change Description	2402 R8
	Addition	**Mature B-cell neoplasms**
Chronic lymphocytic leukemia (CLL), NOS	No change	Chronic lymphocytic leukemia (CLL), NOS
Chronic lymphocytic leukemia (CLL), B-cell / small lymphocytic lymphoma (SLL)	Replacement	Chronic lymphocytic leukemia/small lymphocytic lymphoma
	Addition	**Splenic B-cell lymphomas and leukemias**
Hairy cell leukemia	No change	Hairy cell leukemia
Hairy cell leukemia variant	Replacement	Splenic B-cell lymphoma/leukemia with prominent nucleoli
Monoclonal B-cell lymphocytosis	Removal	
Prolymphocytic leukemia (PLL), NOS	Removal	
PLL, B-cell	Removal	
PLL, T-cell	Replacement	T-prolymphocytic leukemia
Other Leukemia, NOS	No change	Other Leukemia, NOS
Other Leukemia	No change	Other leukemia

Hodgkin and Non-Hodgkin Lymphoma

- **Q395 ("Specify the lymphoma histology")**
  - Update: Disease classifications have been updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community. (See (Alaggio, 2022)
    ~See table below for detailed list of changes
  - Rationale: Capture current published and relevant disease classifications.

2402 R7	Data Change Description	2402 R8
Hodgkin lymphoma Codes	Replacement	**Hodgkin lymphoma**

Hodgkin lymphoma, not otherwise specified	Replacement	Classic Hodgkin lymphoma
Lymphocyte depleted	No change	Lymphocyte depleted
Lymphocyte-rich	No change	Lymphocyte-rich
Mixed cellularity	No change	Mixed cellularity
Nodular sclerosis	No change	Nodular sclerosis
Nodular lymphocyte predominant Hodgkin lymphoma	No change	Nodular lymphocyte predominant Hodgkin lymphoma
Non-Hodgkin Lymphoma Codes	Removal	
	Addition	**Burkitt lymphoma**
Burkitt lymphoma	No change	Burkitt lymphoma
B-cell Neoplasms	Removal	
	Addition	**Large B-cell lymphomas**
Diffuse large B-cell Lymphoma (cell of origin unknown)	Replacement	Diffuse large B-cell lymphoma, NOS
Diffuse, large B-cell lymphoma-Germinal center B-cell type	Replacement	Diffuse large B-cell lymphoma, Germinal Center B-cell subtype
Diffuse, large B-cell lymphoma-Activated B-cell type (non-GCB)	Replacement	Diffuse large B-cell lymphoma, Activated B-cell subtype
T-cell / histiocytic rich large B-cell lymphoma	Replacement	T-cell/histiocyte-rich large B-cell lymphoma
High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements	Replacement	Diffuse large B-cell lymphoma/ high grade B-cell lymphoma with MYC and BCL2 rearrangements
	Addition	Diffuse large B-cell lymphoma/ high grade B-cell lymphoma with MYC and BCL6 rearrangements
	Addition	Diffuse large B-cell lymphoma/ high grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements
ALK+ large B-cell lymphoma	Replacement	ALK-positive large B-cell lymphoma
Large B-cell lymphoma with IRF4 rearrangement	No change	Large B-cell lymphoma with IRF4 rearrangement
Burkitt-like lymphoma with 11q aberration	Replacement	High-grade B-cell lymphoma with 11q aberrations
Lymphomatoid granulomatosis	No change	Lymphomatoid granulomatosis
EBV+ DLBCL, NOS	Replacement	EBV-positive diffuse large B-cell lymphoma
DLBCL associated with chronic inflammation	Replacement	Diffuse large B-cell lymphoma associated with chronic inflammation
	Addition	Fibrin-associated large B-cell lymphoma
	Addition	Fluid overload-associated large B-cell lymphoma
Plasmablastic lymphoma	No change	Plasmablastic lymphoma

Primary cutaneous DLBCL, leg type	Replacement	Primary cutaneous diffuse large B-cell lymphoma, leg type
Intravascular large B-cell lymphoma	No change	Intravascular large B-cell lymphoma
Primary mediastinal (thymic) large B-cell lymphoma	Replacement	Primary mediastinal large B-cell lymphoma
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma	Replacement	Mediastinal grey zone lymphoma
High-grade B-cell lymphoma, NOS	No change	High-grade B-cell lymphoma, NOS
	Addition	**Primary large B-cell lymphoma of immune-privileged sites**
Primary diffuse, large B-cell lymphoma of the CNS	Replacement	Primary large B-cell lymphoma of the CNS
	Addition	Primary large B-cell lymphoma of the vitreoretina
	Addition	Primary large B-cell lymphoma of the testis
	Addition	**KSHV/HHV8-associated B-cell lymphoid proliferations and lymphomas**
Primary effusion lymphoma	No change	Primary effusion lymphoma
HHV8+ DLBCL, NOS	Replacement	KSHV/HHV8-positive diffuse large B-cell lymphoma
	Addition	**Lymphoplasmacytic lymphoma**
Waldenstrom macroglobulinemia / Lymphoplasmacytic lymphoma	Replacement	Lymphoplasmacytic lymphoma
	Addition	IgM-LPL/Waldenstron macroglobulinemia
	Addition	Non-IgM-LPL/Waldenstron macroglobulinemia
	Addition	**Marginal zone lymphoma**
Extranodal marginal zone B-cell lymphoma of mucosal associated lymphoid tissue type (MALT)	Replacement	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
	Addition	Primary cutaneous marginal zone lymphoma
Nodal marginal zone B-cell lymphoma (± monocytoid B-cells)	Replacement	Nodal marginal zone lymphoma
Pediatric nodal marginal zone lymphoma	Replacement	Pediatric marginal zone lymphoma
	Addition	**Splenic B-cell lymphomas**
Splenic marginal zone B-cell lymphoma	Replacement	Splenic marginal zone lymphoma
Splenic diffuse red pulp small B-cell lymphoma	No change	Splenic diffuse red pulp small B-cell lymphoma

Splenic B-cell lymphoma/leukemia, unclassifiable	Replacement	Splenic, B-cell lymphoma/leukemia with prominent nucleoli
	Addition	**Follicular lymphoma**
Follicular, predominantly small cleaved cell (Grade I follicle center lymphoma)	No change	Follicular, predominantly small cleaved cell (Grade I follicle center lymphoma)
Follicular, mixed, small cleaved and large cell (Grade II follicle center lymphoma)	No change	Follicular, mixed, small cleaved and large cell (Grade II follicle center lymphoma)
Follicular, predominantly large cell (Grade IIIA follicle center lymphoma)	No change	Follicular, predominantly large cell (Grade IIIA follicle center lymphoma)
Follicular, predominantly large cell (Grade IIIB follicle center lymphoma)	No change	Follicular, predominantly large cell (Grade IIIB follicle center lymphoma)
Follicular, predominantly large cell (Grade IIIA vs IIIB not specified)	No change	Follicular, predominantly large cell (Grade IIIA vs IIIB not specified)
Follicular (grade unknown)	No change	Follicular (grade unknown)
Pediatric-type follicular lymphoma	No change	Paediatric-type follicular lymphoma
Duodenal-type follicular lymphoma	No change	Duodenal-type follicular lymphoma
	Addition	**Cutaneous follicle center lymphoma**
Primary cutaneous follicle center lymphoma	No change	Primary cutaneous follicle center lymphoma
	Addition	**Mantle cell lymphoma**
Mantle cell lymphoma	No change	Mantle cell lymphoma
	Addition	Leukemic non-nodal mantle cell lymphoma
	Addition	**Transformations of indolent B-cell lymphomas**
	Addition	Transformations of indolent B-cell lymphomas
	Addition	**Lymphomas associated with immune deficiency and dysregulation**
Classical Hodgkin lymphoma PTLD	No change	Classical Hodgkin lymphoma PTLD
Florid follicular hyperplasia PTLD	Removal	
Infectious mononucleosis PTLD	No change	Infectious mononucleosis PTLD
Plasmacytic hyperplasia PTLD	Replacement	Hyperplasia arising in immune deficiencies (e.g. PTLD)
Polymorphic PTLD	Replacement	Polymorphic lymphoproliferative disorders arising in immune deficiency/dysregulation
EBV+ mucocutaneous ulcer	Replacement	EBV-positive mucocutaneous ulcer
Monomorphic PTLD (B- and T-/NK-cell types)	No change	Monomorphic PTLD (B- and T-/NK-cell types)

	Addition	**Mature T-cell and NK-cell leukemias**
T-cell large granular lymphocytic leukemia	Replacement	T-large granular lymphocytic leukemia
Chronic lymphoproliferative disorder of NK cells	Replacement	NK-large granular lymphocytic leukemia
Adult T-cell lymphoma / leukemia (HTLV1 associated)	Replacement	Adult T-cell leukemia/lymphoma
Sezary syndrome	No change	Sezary syndrome
Aggressive NK-cell leukemia	No change	Aggressive NK-cell leukemia
		Primary cutaneous T-cell lymphomas
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder	Replacement	Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder
Primary cutaneous acral CD8+ T-cell lymphoma	Replacement	Primary cutaneous acral CD8-positive lymphoproliferative disorder
Mycosis fungoides	No change	Mycosis fungoides
Primary cutaneous CD30+ T-cell lymphoproliferative disorders [Primary cutaneous anaplastic large-cell lymphoma (C-ALCL), lymphoid papulosis]	Replacement	Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis
	Addition	Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma	No change	Subcutaneous panniculitis-like T-cell lymphoma
Primary cutaneous γδ T-cell lymphoma	No change	Primary cutaneous gamma/delta T-cell lymphoma
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma	Replacement	Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma
	Addition	Primary cutaneous peripheral T-cell lymphoma, NOS
	Addition	**Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas**
Indolent T-cell lymphoproliferative disorder of the GI tract	Replacement	Indolent T-cell lymphoma of the gastrointestinal tract
	Addition	Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract
Enteropathy-type T-cell lymphoma	Replacement	Enteropathy-associated T-cell lymphoma
Monomorphic epitheliotropic intestinal T-cell lymphoma	No change	Monomorphic epitheliotropic intestinal T-cell lymphoma
	Addition	Intestinal T-cell lymphoma, NOS

	Addition	**Hepatosplenic T-cell lymphoma**
Hepatosplenic T-cell lymphoma	No change	Hepatosplenic T-cell lymphoma
	Addition	**Anaplastic large cell lymphoma**
Anaplastic large-cell lymphoma (ALCL), ALK positive	Replacement	ALK-positive anaplastic large cell lymphoma
Anaplastic large-cell lymphoma (ALCL), ALK negative	Replacement	ALK-negative anaplastic large cell lymphoma
Breast implant–associated anaplastic large-cell lymphoma	Replacement	Breast implant-associated anaplastic large cell lymphoma
	Addition	**Nodal T-follicular helper (TFH) cell lymphoma**
Angioimmunoblastic T-cell lymphoma	Replacement	Nodal TFH cell lymphoma, angioimmunoblastic-type
Follicular T-cell lymphoma	Replacement	Nodal TFH cell lymphoma, follicular-type
Nodal peripheral T-cell lymphoma with TFH phenotype	Replacement	Nodal TFH cell lymphoma, NOS
	Addition	**Other peripheral T-cell lymphomas**
Peripheral T-cell lymphoma (PTCL), NOS	Replacement	Peripheral T-cell lymphoma, not otherwise specified
	Addition	**EBV-positive NK/T-cell lymphomas**
	Addition	EBV-positive nodal T- and NK-cell lymphoma
Extranodal NK / T-cell lymphoma, nasal type	Replacement	Extranodal NK/T-cell lymphoma
	Addition	**EBV-positive T- and NK-cell lymphoid proliferations and lymphomas of childhood**
Systemic EBV+ T-cell lymphoma of childhood	Replacement	Systemic EBV-positive T-cell lymphoma of childhood
Other B-cell lymphoma	No change	Other B-cell lymphoma
Other T-cell / NK-cell lymphoma	No change	Other T-cell / NK-cell lymphoma

Multiple Myeloma / Plasma Cell Disorder (PCD)

- **Q413 ("Specify the multiple myeloma / plasma cell disorder (PCD) classification")**
  - Update: Disease classifications have been updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community.
    ~See table below for detailed list of changes
  - Rationale: Capture current published and relevant disease classifications.

2402 R7	Data Change Description	2402 R8

Multiple myeloma	No change	Multiple myeloma
Multiple myeloma-light chain only	No change	Multiple myeloma-light chain only
Multiple myeloma-non-secretory	No change	Multiple myeloma-non-secretory
Plasma cell leukemia	No change	Plasma cell leukemia
Solitary plasmacytoma (no evidence of myeloma)	Replacement	Plasmacytoma
Smoldering myeloma	No change	Smoldering myeloma
Amyloidosis	Replacement	Immuno-globulin-related (AL) amyloidosis
	Addition	**Plasma cell neoplasm with associated paraneoplastic syndrome**
Osteosclerotic myeloma/POEMS syndrome	Replacement	POEMS syndrome
Monoclonal gammopathy of renal significance (MGRS)	No change	Monoclonal gammopathy of renal significance (MGRS)
Other plasma cell disorder	No change	Other plasma cell disorder

- **Q418 ("Select monoclonal immunoglobulin deposition disease (MIDD) subtype")**
  - Update: The option "Light and heavy chain deposition disease (LHCDD)" has been updated to "Monoclonal immunoglobulin deposition disease" in the option list. This change was made to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community.
  - Rationale: Capture current published and relevant disease classifications.
- **Q420 ("Solitary plasmacytoma was")**
  - Update: The option "Extramedullary" has been updated to "Extraosseous plasmacytoma" and the option "Bone derived" has been updated to "Solitary plasmacytoma of bone" in the option list. These changes were made to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community.
  - Rationale: Capture current published and relevant disease classifications.

Solid Tumors

- **Q460 ("Specify the solid tumor classification")**
  - Update: Disease classifications have been updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community.
    ~See table below for detailed list of changes
  - Rationale: Capture current published and relevant disease classifications.

2402 R7	Data Change Description	2402 R8
	Addition	**Breast cancer**
Breast cancer	No change	Breast cancer
	Addition	**Tumors of the Head/neck**
Head/neck	No change	Tumors of the Head/neck
	Addition	**Digestive system tumors**
	Addition	Tumor of the esophagus and Gastro-esophageal (GE) junction
Gastric	Replacement	Tumors of the stomach
Hepatobilary	Replacement	Tumors of liver and intrahepatic bile ducts
Colorectal	No change	Colorectal
Pancreatic	No change	Pancreatic
	Addition	**Central nervous system tumors**
	Addition	Atypical teratoid rhabdoid tumor (ATRT)
Central nervous system tumor, including CNS PNET	No change	Central nervous system tumor, including CNS PNET
Medullobastoma	No change	Medulloblastoma
	Addition	Diffuse intrinsic pontine glioma (DIPG)
	Addition	Glioblastoma multiforme (GBM)
	Addition	Ependymoma
	Addition	**Soft tissue or bone tumors**
Bone sarcoma (excluding Ewing family tumors)	No change	Bone sarcoma (excluding Ewing family tumors)
Ewing family tumors of bone (including PNET)	No change	Ewing family tumors of bone (including PNET)
Ewing family tumors, extraossesous (include PNET)	No change	Ewing family tumors, extraossesous (include PNET)
Soft tissue sarcoma (excluding Ewing family tumors)	Replacement	Other Soft tissue sarcoma (excluding Ewing family tumors)
	Addition	Desmoplastic small round cell tumors
	Addition	Myxoid round cell sarcoma
Synovial Sarcoma	No change	Synovial Sarcoma

Fibrosarcoma	Removal	
Hemangiosarcoma	Removal	
Liposarcoma	Removal	
Leiomyosarcoma	Removal	
Lymphangio sarcoma	Removal	
Neurogenic sarcoma	Replacement	Malignant Peripheral Nerve Sheath Tumor
Rhabdomyosarcoma	No change	Rhabdomyosarcoma
	Addition	**Tumors of endocrine organs**
Neuroblastoma	No change	Neuroblastoma
Germ cell tumor, gonadal	No change	Germ cell tumor, gonadal
Germ cell tumor, extragonadal	No change	Germ cell tumor, extragonadal
Thymoma	Removal	
	Addition	**Thoracic Tumors**
	Addition	Adenocarcinoma
Lung Cancer, non small cell	No change	Lung Cancer, non small cell
Lung, small cell	No change	Lung, small cell
Lung, not otherwise specified	No change	Lung, not otherwise specified
	Addition	Tumor of the pleura (Mesothelioma)
	Addition	Squamous carcinoma
Mediastinal neoplasm	Removal	
	Addition	**Skin Tumors**
Malignant Melanoma	Replacement	Melanoma
	Addition	**Genitourinary Tumors**
Ovarian (epithelial)	No change	Ovarian (epithelial)
Vaginal	No change	Vaginal
Prostate	No change	Prostate
Testicular	No change	Testicular
Cervical	Removal	
Renal cell	No change	Renal cell
External genitalia	Removal	
	Addition	**Pediatric focused Tumors**

Wilms tumor	No change	Wilms tumor
Retinoblastoma	No change	Retinoblastoma
	Addition	Malignant Rhabdoid Tumor of the Kidney
	Addition	**Other solid tumors**
Solid tumor, not otherwise specified	No change	Solid tumor, not otherwise specified
Other solid tumor	No change	Other solid tumor

Inherited Bone Marrow Failure Syndromes

- **Q465 ("Specify the inherited bone marrow failure syndrome classification")**
  - Update: The option "Dyskeratosis congenita" has been updated to "Telomere Biology Disorders including Dyskeratosis congenita (DKC1, TERT, TERC, and other mutations)", "Severe congenital neutropenia (including Kostmann syndrome)" has been updated to "Severe congenital neutropenia (Elastase deficiency / ELANE or Kostmann disease / HAX1 mutations)" and the option "Shwachman-Diamond" has been updated to "Shwachman-Diamond Syndrome (DNAJC21, EFL1, or SBDS mutations)" in the option list. Additional two options have been added: "Germline SAMD9 variant (MIRAGE Syndrome)" and "Germline SAMD9L variant (SAMD9L-related Ataxia Pancytopenia Syndrome)." These changes were made to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community.
  - Rationale: Capture current published and relevant disease classifications.

Disorders of the Immune System

- **Q502 ("Specify the disorder of immune system classification")**
  - Update: Disease classifications have been updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community.
    ~See table below for detailed list of changes
  - Rationale: Capture current published and relevant disease classifications.

2402 R7	**Data Change Description**	**2402 R8**
	Addition	**Severe Combined Immunodeficiencies**
	Addition	SCID, T- B- NK-, NOS
Adenosine deaminase (ADA) deficiency / severe combined immunodeficiency (SCID)	Replacement	SCID, T- B- NK-, Adenosine deaminase (ADA) deficiency
Reticular dysgenesis	Replacement	SCID, T- B- NK-, reticular dysgenesis

	Addition	SCID, T- B- NK+, RAG 1/2 deficiency
	Addition	SCID, T- B- NK+, DCLRE1C (Artemis) deficiency
Absence of T and B cells SCID	Removal	
Absence of T, normal B cell SCID	Replacement	SCID, T- B+ NK+, ILR alpha deficiency
Other SCID	No change	Other SCID (with known genetic mutation)
SCID, not otherwise specified	No change	SCID, not otherwise specified
	Addition	**Combined Immunodeficiencies**
Bare lymphocyte syndrome	Replacement	MHC Class II Deficiency (Bare Lymphocyte Syndrome)
Omenn syndrome	No change	Omenn syndrome
	Addition	ZAP-70 deficiency
CD40 ligand deficiency	No change	CD40 ligand deficiency
	Addition	DOCK8 Deficiency
	Addition	**Combined Immunodeficiencies with Associated or Syndromic Features**
Wiskott-Aldrich syndrome	No change	Wiskott-Aldrich syndrome
Cartilage-hair hypoplasia	No change	Cartilage-hair hypoplasia
Ataxia telangiectasia	No change	Ataxia telangiectasia
DiGeorge anomaly	No change	DiGeorge anomaly
	Addition	NEMO Deficiency Syndrome
	Addition	**Predominately Antibody deficiencies**
Common variable immunodeficiency	No change	Common variable immunodeficiency
	Addition	Activated PI3 Kinase Delta Deficiency Syndrome (APDS1 or PIK3CD)
	Addition	**Diseases of immune dysregulation, hemophagocytic lymphohistiocytosis**
Chediak-Higashi syndrome	No change	Chediak-Higashi syndrome
Griscelli syndrome type 2	No change	Griscelli syndrome type 2
Hermansky-Pudlak syndrome type 2	No change	Hermansky-Pudlak syndrome type 2

Other pigmentary dilution disorder	No change	Other pigmentary dilution disorder
	Addition	**Diseases of immune dysregulation, EBV susceptibility**
X-linked lymphoproliferative syndrome	Replacement	SAP Deficiency (XIAP-1)
	Addition	XIAP-2 Deficiency
	Addition	ITK deficiency
	Addition	**Diseases of immune dysregulation, syndromes with Autoimmunity and Others, NOS**
	Addition	Autoimmune Lymphoproliferative Syndrome (ALPS)
	Addition	IPEX, Immune Dysregulation Polyendocrinopathy, enteropathy X-linked (FOXP3 deficiency)
	Addition	CTLA4 deficiency
	Addition	LRBA Deficiency
	Addition	STAT3 Gain of Function
	Addition	**Congenital defects of phagocyte**
Chronic granulomatous disease	No change	Chronic granulomatous disease
Leukocyte adhesion deficiencies, including GP180, CD-18, LFA and WBC adhesion deficiencies	Replacement	Leukocyte adhesion deficiencies
	Addition	GATA2 deficiency
Neutrophil actin deficiency	Replacement	Neutropenia with combined immune deficiency (MKL1 deficiency, Actin deficiency)
	Addition	**Other Immunodeficiencies**
	Addition	STAT1 Gain of Function
Other immunodeficiencies	No change	Other immunodeficiencies
Immune deficiency, not otherwise specified	No change	Immune deficiency, not otherwise specified
HIV infection	No change	HIV infection

Histiocytic Disorders

- **Q515 ("Specify the histiocytic disorder classification")**

- Update: Disease classifications have been updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community.
  ~See table below for detailed list of changes
- Rationale: Capture current published and relevant disease classifications.

2402 R7	Data Change Description	2402 R8
Hemophagocytic lymphohistiocytosis (HLH)	Removal	
	Addition	**Diseases of immune dysregulation, Familial Hemophagocytic Lymphohistiocytosis (FHL)**
	Addition	Familial Hemophagocytic Lymphohistiocytosis, Perforin deficiency (FHL2)
	Addition	Familial Hemophagocytic Lymphohistiocytosis, UNC13D (FHL3)
	Addition	Familial Hemophagocytic Lymphohistiocytosis, STX11 (FHL4)
	Addition	Familial Hemophagocytic Lymphohistiocytosis, STXBP2 (FHL5)
	Addition	Familial Hemophagocytic Lymphohistiocytosis, other mutations
	Addition	Familial Hemophagocytic Lymphohistiocytosis, no mutation identified
Langerhans cell histiocytosis (histiocytosis-X)	No change	Langerhans cell histiocytosis (histiocytosis-X)
Hemophagocytosis (reactive or viral associated)	No change	Hemophagocytosis (reactive or viral associated)
Malignant histiocytosis	No change	Malignant histiocytosis
Other histiocytic disorder	No change	Other histiocytic disorder
Histiocytic disorder, not otherwise specified	No change	Histiocytic disorder, not otherwise specified

References

Alaggio, R. e. (2022, June 22). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. *Springer Nature*, 1721-1748.

Arber, D. e. (2022, September 15). International Consensus Classification of Myeloid Neoplasms and Acute Leukemia:. *Blood*, 1200-1228.

Hartmut Dohner, A. H. (2022, September 22). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood*, 1345-1377.

Khoury, J. D. (2022, June 22). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Springer Nature*, 1703-1719.